目的    研究蒽环类联合紫杉类方案对三阴型乳腺癌进行新辅助化疗的疗效，应用动态增强磁共振成像（MRI）及组织病理学进行疗效评价。 方法    选择2008年1月至2011年12月北京大学第一医院乳腺疾病中心初始实施蒽环类联合紫杉类新辅助化疗并完成手术的三阴型乳腺癌病人为研究对象。疗效评价包括动态增强MRI临床评价及组织病理学评价。定义MRI评价包括临床完全缓解、临床部分缓解为临床评价有效，计算临床有效率；定义病理分级G3~G5为病理评价有效，计算病理有效率。 结果    共诊治1190例新发乳腺癌，其中三阴型乳腺癌129例（占10.8%），41例符合入组标准，新辅助治疗临床评价有效率为65.85%（27/41），病理评价有效率为85.37%（35/41），其中病理完全缓解率（pCR）为36.59%（15/41），新辅助治疗MRI评价与病理评价符合率为77.1%。 结论    蒽环类联合紫衫类方案是治疗三阴型乳腺癌的有效方法。动态增强MRI能准确评价三阴型乳腺癌新辅助化疗疗效，并与病理评价相符合。

Combination of anthracycline and taxane as neoadjuvant chemotherapy on patients with triple-negative breast cancer        HUANG Qing-yun, YE Jing-ming, XU Ling, et al. Breast Disease Center, Peking University First Hospital, Beijing 100034, China
Corresponding author: YE Jing-ming, E-mail: md_ye@sina.com
Abstract    Objective    To study the efficacy of anthracycline combined taxane neoadjuvant chemotherapy in triple-negative breast cancer, and investigate the value of dynamic contrast-enhanced MRI in the evaluation of neoadjuvant chemotherapy. Methods    From January 2008 to December 2011, patients diagnosed as triple-negative breast cancer (ER-ve, PR-ve, HER2-ve) and received nthracycline combined taxane neoadjuvant chemotherapy in Breast Disease Center of Peking University were selected. Efficacy of neoadjuvant chemotherapy on patients with triple-negative breast cancer was evaluated after comparison and analysis of dynamic contrast-enhanced MRI and pathological efficacy. The treatment efficacy was clinically assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. CR and PR were defined as clinical effective, and the pathologic response was evaluated according to the Miller-Payne grading system. G3-G5/pCR were defined as pathological effective. All the effective rates were calculated. Pathological Complete Response (pCR) rate would be evaluated independently. Results    A total of 1190 paints with breast cancer were diagnosed. Among them, 129 patients (10.8%) were triple-negative breast cancer. Forty-one patients were enrolled in the study. The clinical effective rate was 65.85% (27/41) and the pathological effective rate was 85.37% (35/41). For all the patients, pCR rate was 36.59% (15/41).The consistent rate between MRI and pathological evaluation was 77.1%. Conclusion    Anthracycline combined with taxane are proved effective as neoadjuvant chemotherapy for patients with triple-negative breast cancer. Dynamic contrast-enhanced MRI can evaluate the response of neoadjuvant chemotherapy on patient with triple-negative breast cancer, and also highly consistent to the result of pathological efficacy.